See more : Public Joint – Stock Company Ruspolymet (RUSP.ME) Income Statement Analysis – Financial Results
Complete financial analysis of ProMIS Neurosciences, Inc. (PMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProMIS Neurosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- JBS S.A. (JBSS3.SA) Income Statement Analysis – Financial Results
- Top Union Electronics Corp. (6266.TWO) Income Statement Analysis – Financial Results
- National Fertilizer Company Ltd (9517.SR) Income Statement Analysis – Financial Results
- The Andersons, Inc. (ANDE) Income Statement Analysis – Financial Results
- ATI Inc. (ATD.DE) Income Statement Analysis – Financial Results
ProMIS Neurosciences, Inc. (PMN)
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.14K | 1.40K | 920.18 | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Cost of Revenue | 10.44M | 21.78M | 5.85M | 3.18M | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.44M | -21.78M | -5.84M | -3.18M | -4.73M | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Gross Profit Ratio | 0.00% | 0.00% | -71,796.88% | -227,041.82% | -514,509.20% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.88M | 16.09M | 4.95M | 2.50M | 3.63M | 5.44M | 3.15M | 1.39M | 763.96K | 1.27M | 1.77M | 2.04M | 3.25M | 3.62M | 3.27M | 6.06M | 2.95M | 944.20K |
| General & Administrative | 7.39M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.38M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 536.21K | 1.20M | 1.17M | 824.00K | 1.22M | 885.47K | 351.62K |
| Other Expenses | -5.81M | 115.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| Operating Expenses | 8.45M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Cost & Expenses | 18.90M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Interest Income | 0.00 | 0.00 | 4.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 193.63K | 0.00 | 0.00 |
| Interest Expense | -201.39K | 282.06K | 415.03K | 0.00 | 0.00 | 0.00 | 5.65K | 15.89K | 23.98K | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.04K | 15.19K | 45.83K | 12.33K | 6.55K | 4.90K | 5.31K | 4.96K | 5.50K | 14.78K | 49.45K | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| EBITDA | -17.81M | -29.88M | -9.33M | -4.43M | -5.66M | -7.46M | -4.78M | -2.55M | -1.51M | -2.88M | -2.02M | -2.15M | -2.49M | -3.13M | -4.61M | -3.90M | -6.82M | -3.62M |
| EBITDA Ratio | 0.00% | 0.00% | -100,802.23% | -315,985.67% | -614,617.22% | -2,139,026.95% | -60,699.29% | -127,551.65% | -9,929.36% | -1,508.22% | -4,408.57% | -2,730.51% | -261.17% | -2,617.02% | -2,013.48% | -1,470.16% | -1,645.59% | -2,724.12% |
| Operating Income | -18.90M | -23.38M | -8.25M | -4.44M | -5.66M | -7.46M | -4.78M | -2.56M | -1.51M | -2.04M | -2.19M | -2.56M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Operating Income Ratio | 0.00% | 0.00% | -101,363.57% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,766.72% | -127,799.59% | -10,519.49% | -1,519.23% | -4,510.18% | -2,813.90% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,382.95% |
| Total Other Income/Expenses | 1.39M | 7.20M | -1.50M | 1.22M | 0.00 | 0.00 | -5.65K | -11.82K | -17.28K | -853.75K | 0.00 | 40.59K | 13.50 | 3.34M | 0.00 | 4.08M | 3.32M | 1.98M |
| Income Before Tax | -17.51M | -18.06M | -9.24M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | -113,562.83% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| Income Tax Expense | -167.90K | -5.32M | 415.03K | 0.14 | 0.00 | -156.24K | 5.65K | 11.82K | 17.28K | 0.91 | -2.29K | 2.55M | 3.43M | 4.76M | 4.08M | 6.99M | 3.67M | 1.69M |
| Net Income | -17.51M | -12.74M | -9.66M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Net Income Ratio | 0.00% | 0.00% | -118,662.24% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| EPS | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| EPS Diluted | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| Weighted Avg Shares Out | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
| Weighted Avg Shares Out (Dil) | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that company management will...
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's Disease Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of...
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief...
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodies Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodies
ProMIS Neurosciences Issues Letter to Shareholders
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases...
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer
ProMIS Neurosciences Announces Publication on Novel Target for ALS
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study
Source: https://incomestatements.info
Category: Stock Reports